Armata Pharmaceuticals Achieved Full Enrollment In Its Tailwind Phase 2 Study Of Inhaled AP-PA02 In Patients With NCFB And Chronic Pulmonary Pseudomonas Aeruginosa Infection, Topline Data Is Expected In The Second Half Of 2024

7/11/24 7:09:07 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ARMP alert in real time by email

Get the next $ARMP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARMP

Date	Price Target	Rating	Analyst

More analyst ratings

$ARMP
Financials

Live finance-specific insights

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023 Repurchased $11.0 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select cor
11/1/23 4:15:00 PM ET
$ARMP
$INVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Repurchased $9.2 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives
8/2/23 4:05:00 PM ET
$ARMP
$INVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Innoviva Reports First Quarter 2022 Financial Results
Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue
4/27/22 5:11:00 PM ET
$ARMP
$ETTX
$INVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

$ARMP
Press Releases

Fastest customizable press release news feed in the world

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
LOS ANGELES, Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 1:15pm ET at the 5th Annual Phage Futures Annual Meeting, which is being held November 19th in Boston, MA. For more information: https://phagefuturesusa.com/events/phage-futures-2024 About Armata Pharmaceutical
11/19/24 7:00:00 AM ET
$ARMP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2024, and provided a corporate update. Third Quarter 2024 and Recent Developments: Completed enrollment of the Phase 2 study ("Tailwind") of inhaled AP-PA02 in patients with non-cystic fibrosis bronchiectasis ("NCFB") and chronic
11/13/24 4:05:00 PM ET
$ARMP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025 LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has achieved full enrollment (n=50) of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus (S. aureus) bacteremia. Armata anticipates topline data from the diSArm study in the first quarter of 2025.
11/12/24 7:00:00 AM ET
$ARMP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller. "We are delighted to welcome David to the Armata t
8/15/24 4:45:00 PM ET
$ARMP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2023, and provided a corporate update. Second Quarter 2023 and Recent Developments: Announced leadership transition whereby world‐renowned healthcare leader and former Innoviva Board member Dr. Deborah L. Birx has been appointed Armata's new Chi
8/14/23 7:00:00 AM ET
$ARMP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t
7/11/23 8:00:00 AM ET
$ARMP
$INVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

Armata Pharmaceuticals Achieved Full Enrollment In Its Tailwind Phase 2 Study Of Inhaled AP-PA02 In Patients With NCFB And Chronic Pulmonary Pseudomonas Aeruginosa Infection, Topline Data Is Expected In The Second Half Of 2024

Chat with this insight

Recent Analyst Ratings for
$ARMP

$ARMP
SEC Filings

Armata Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

SEC Form 10-Q filed by Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ARMP
Financials

Live finance-specific insights

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Reports First Quarter 2022 Financial Results

$ARMP
Press Releases

Fastest customizable press release news feed in the world

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

$ARMP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Armata Pharmaceuticals with a new price target

$ARMP
Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

Armata Pharmaceuticals Achieved Full Enrollment In Its Tailwind Phase 2 Study Of Inhaled AP-PA02 In Patients With NCFB And Chronic Pulmonary Pseudomonas Aeruginosa Infection, Topline Data Is Expected In The Second Half Of 2024

Armata Pharmaceuticals To Present Viruses Of Microbes 2024

$ARMP
Leadership Updates

Live Leadership Updates

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

$ARMP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, Finance, and PFO House David Duane

SEC Form 3 filed by new insider House David Duane

New insider Kyme Pierre claimed ownership of 10,000 shares (SEC Form 3)

Armata Pharmaceuticals Achieved Full Enrollment In Its Tailwind Phase 2 Study Of Inhaled AP-PA02 In Patients With NCFB And Chronic Pulmonary Pseudomonas Aeruginosa Infection, Topline Data Is Expected In The Second Half Of 2024

Chat with this insight

Recent Analyst Ratings for $ARMP

$ARMP SEC Filings

Armata Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

SEC Form 10-Q filed by Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ARMP Financials

Live finance-specific insights

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Reports First Quarter 2022 Financial Results

$ARMP Press Releases

Fastest customizable press release news feed in the world

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

$ARMP Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Armata Pharmaceuticals with a new price target

$ARMP Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

Armata Pharmaceuticals Achieved Full Enrollment In Its Tailwind Phase 2 Study Of Inhaled AP-PA02 In Patients With NCFB And Chronic Pulmonary Pseudomonas Aeruginosa Infection, Topline Data Is Expected In The Second Half Of 2024

Armata Pharmaceuticals To Present Viruses Of Microbes 2024

$ARMP Leadership Updates

Live Leadership Updates

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

$ARMP Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, Finance, and PFO House David Duane

SEC Form 3 filed by new insider House David Duane

New insider Kyme Pierre claimed ownership of 10,000 shares (SEC Form 3)

Recent Analyst Ratings for
$ARMP

$ARMP
SEC Filings

$ARMP
Financials

$ARMP
Press Releases

$ARMP
Analyst Ratings

$ARMP
Market Insights

$ARMP
Leadership Updates

$ARMP
Insider Trading